March 13, 2018 / 11:13 AM / 3 months ago

BRIEF-Bellicum Announces Interim Results Showing Low Rates Of Cancer Recurrence In Pediatric AML Patients Treated With BPX-501

March 13 (Reuters) - Bellicum Pharmaceuticals Inc:

* BELLICUM ANNOUNCES INTERIM RESULTS SHOWING LOW RATES OF CANCER RECURRENCE IN PEDIATRIC AML PATIENTS TREATED WITH BPX-501

* BELLICUM PHARMA - WORKING WITH INVESTIGATORS & U.S. FDA TO DEVELOP PROTOCOL FOR POTENTIAL U.S. REGISTRATION STUDY IN PEDIATRIC PATIENTS

* BELLICUM PHARMA - EXPECTS TO INITIATE POTENTIAL U.S. REGISTRATION STUDY IN PEDIATRIC PATIENTS BY END OF 2018

* BELLICUM PHARMA - FROM BP-004 STUDY, CO REPORTED HIGH RATES OF DISEASE-FREE SURVIVAL & OVERALL SURVIVAL IN PEDIATRIC PATIENTS WITH PID Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below